Loading organizations...
MedRhythms, Inc. is a company.
MedRhythms, Inc. develops next-generation neurotherapeutics focused on improving walking, mobility, and related functional outcomes for individuals with neurological conditions. The company leverages a software platform to develop and refine prescription medical devices that utilize music and rhythm for neurorehabilitation. Their offerings include InTandem, designed for adults recovering from chronic stroke, and MOVIVE, aimed at individuals with Parkinson's Disease.
The company was founded in 2015 by Brian Harris, who serves as Co-Founder and Chief Scientific Officer, and Owen McCarthy, Co-Founder and former President. Their insight stemmed from extensive research supporting the efficacy of music and rhythm in walking rehabilitation, leading them to apply Neurologic Music Therapy (NMT) within a medical device framework.
MedRhythms serves patients afflicted with neurologic injury or disease, particularly those with chronic stroke and Parkinson's Disease, who require assistance with walking and mobility. The company's vision centers on transforming patient lives by providing accessible, effective neurotherapeutics that empower greater functional independence through advanced rhythmic auditory stimulation.
MedRhythms, Inc. has raised $5.3M across 1 funding round.
MedRhythms, Inc. has raised $5.3M in total across 1 funding round.
MedRhythms, Inc. is a neurorehabilitation company developing next-generation digital therapeutics that use a proprietary platform combining sensors, software, music, and neuroscience to improve walking, mobility, and functional outcomes for patients with neurological conditions like stroke, multiple sclerosis, and Parkinson's disease.[1][2] The platform delivers Rhythmic Auditory Stimulation (RAS), an evidence-based intervention, enabling at-home therapy that scales beyond limited clinical settings, serving chronic stroke survivors and others with gait disorders while partnering with top rehabilitation hospitals.[1][2][3] With $5.7M in total funding across three rounds, the company has achieved milestones like FDA listing for its InTandem™ (MR-001) product in 2023 and a collaboration with Universal Music Group for curated music content.[4][6]
Founded in 2015 by Co-Founder and CEO Brian Harris, a board-certified Neurologic Music Therapist and one of only 350 professionals worldwide with advanced training in neuroscience and music applications, MedRhythms began as a Neurologic Music Therapy (NMT) practice at Spaulding Rehabilitation Hospital, growing into the most comprehensive NMT program in the U.S.[1][3] Harris and his clinicians delivered over 30,000 hours of patient care using RAS and music interventions; in 2017, spotting scalability limits amid rising demand for gait disorder treatments and clinician shortages, they pivoted to technology, launching a digital platform for home-based neurotherapeutics.[1] Early traction included partnerships with hospitals like Burke Rehabilitation and HHM JFK Johnson, New Markets Tax Credit funding for Maine growth, and investments from Maine Venture Fund.[2][3][6]
MedRhythms rides the digital therapeutics wave in neurorehabilitation, leveraging music's unique ability to engage brain regions for movement, language, and attention—unmatched by other stimuli—amid a $28B annual U.S. outpatient rehab market and 2.5M+ annual stroke/TBI cases.[1][3][6] Timing aligns with post-stroke mobility crises (1 in 6 lifetime risk, over half of 65+ survivors affected) and clinician shortages, amplified by telehealth adoption and AI-driven personalization trends.[1][2][3] Market forces like FDA clearances for prescription digital therapeutics and investor interest in brain health (e.g., Maine-focused funds) favor scalable, non-invasive solutions; MedRhythms influences the ecosystem by advancing RAS evidence, partnering with hospitals and music giants, and expanding NMT accessibility beyond clinics.[1][4][6]
MedRhythms is poised to expand its pipeline across stroke, MS, Parkinson's, and beyond, building on InTandem™'s FDA listing and UMG collaboration to drive adoption in home-based care.[1][4][6] Trends like AI-personalized neurotech, aging populations, and value-based rehab pricing will shape growth, potentially capturing shares of the massive stroke/TBI market through telehealth integrations and further trials.[3] Its influence may evolve from niche NMT leader to mainstream digital neurotherapeutics player, redefining brain health by proving music's scalable power—starting from Harris's hospital roots to global patient impact.[1][5]
MedRhythms, Inc. has raised $5.3M in total across 1 funding round.
MedRhythms, Inc.'s investors include Peter Werth, Jean Hoffman.
MedRhythms, Inc. has raised $5.3M across 1 funding round. Most recently, it raised $5.3M Medrhythms - Series A in June 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 29, 2018 | $5.3M Medrhythms - Series A | Peter Werth | Jean Hoffman |